01
May
Surat (Gujarat) [India], May 1: Concept Medical Inc. (CMI), a global leader in drug delivery devices, has received its third Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) for its novel Sirolimus-coated balloon, Magic Touch SCB, for the treatment of Small Vessels (SV) in coronary arteries. This milestone comes after CMI received IDE approvals for Magic Touch SCB to treat Coronary In-Stent Restenosis (ISR) in September 2022 and Magic Touch PTA to treat “Below the Knee” Peripheral Arterial Diseases (PAD) in February 2022. Small vessel disease affects up to 30% of patients undergoing PCI, and…
